Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies

Autor(es)

Tamura, Rodrigo Esaki ^[1] ; Said, Said Muhammad ^{[2, 3]} ; de Freitas, Leticia Mussin ^[1] ; Sanchez Rubio, Ileana Gabriela ^{[1, 3, 4]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Biol Sci, Rua Pedro Toledo 669, 11 Andar, Diadema, SP - Brazil

^[2] Santa Catarina Hosp, Sao Paulo - Brazil

^[3] Univ Fed Sao Paulo, Thyroid Mol Sci Lab, Sao Paulo, SP - Brazil

^[4] Univ Fed Sao Paulo, Lab Canc Mol Biol, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: DIABETOLOGY & METABOLIC SYNDROME; v. 13, n. 1 JUL 13 2021.
• Citações Web of Science: 0

Resumo

BackgroundCOVID-19 has stroke Brazil harshly, deaths by COVID-19 in Brazil represent almost 13% of the total deaths by COVID-19 in the world, even though Brazilian population represents only 2.6% of the world population. Our aim in this study was to evaluate death and intubation outcomes and risk factors associated with COVID-19, and treatment options focusing on diabetes patients and the use of metformin pre-admission and during hospitalization.MethodsIn this Brazilian single-center study we evaluated 1170 patients hospitalized due to COVID-19. Diabetes patients (n=188) were divided based on their use of pre-hospital and in-hospital metformin (non-met-group and met-group).ResultsIn the total cohort most comorbidities were risk factors for orotracheal intubation and death. The use of chloroquine/hydroxychloroquine was significantly associated with increased death and intubation risk in uni- and multivariate analysis. Diabetes patients showed worst clinical feature compared with non-diabetes patients. In-hospital non-met-group had increased mortality (20.5%) compared to met-group (3.5%) (p=0.0002) and univariable cox proportion hazard regression indicated in-hospital metformin reduced mortality (HR=0.325, p=0.035). Patients that used pre-hospital metformin showed lower severity parameters at hospital admission. (met-group: 2.452.5; non-met-group: 4.25 +/- 3.4). In all the groups older patients showed more severe clinical conditions and high risk of death and intubation.ConclusionEven though this is a single-center study, results from other reports have shown a similar trend, indicating that patients that used metformin during hospitalization have a better prognosis and reduced risk of death. (AU)

• Processo FAPESP: 20/08271-7 - Desenvolvimento de sistema adenoviral de alta capacidade expressando genes com atividade antitumoral
• Beneficiário: Rodrigo Esaki Tamura
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 19/15619-2 - Desenvolvimento de sistema adenoviral de alta capacidade expressando genes com atividade antitumoral
• Beneficiário: Rodrigo Esaki Tamura
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores